Your shopping cart is currently empty

AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition to immune activation and antitumor activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $116 | In Stock | In Stock | |
| 5 mg | $326 | In Stock | In Stock | |
| 10 mg | $489 | - | In Stock | |
| 25 mg | $798 | - | In Stock | |
| 50 mg | $1,090 | Inquiry | Inquiry | |
| 100 mg | $1,480 | Inquiry | Inquiry |
| Description | AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition to immune activation and antitumor activity. |
| In vitro | In vitro, AUNP-12 displayed equipotent antagonism toward PD-L1 and PD-L2 in the rescue of lymphocyte proliferation and effector functions. In human PBMC cells, AUNP-12 was also able to significantly rescue recombinant human PD-L1 and PD-L2 mediated inhibition in vitro, with average EC50 values of 63.3 nM and 44.1 nM against PD-L1 and PD-L2 respectively. [1] |
| In vivo | AUNP-12 acetate rescued the proliferation in the mouse splenocyte assay system, with average EC50 values of 17 nM and 16.6 nM against rmPD-L1 and rmPD-L2 respectively. AUNP-12 (6 hours) showed a Plasma protein binding of 93.9% with plasma stability of more than 60%. AUNP-12 exhibited a half-life of 90 minutes in mouse liver microsomes. In male Balb/c mice, AUNP-12 subcutaneous injection or intravenous injection as a concentration of 3 mg/kg for its PK study. As a result, AUNP-12 shows a low volume of distribution, and the peak plasma levels reach at 0.2-0.4 hours. The absolute bioavailability of AUNP-12 is about 77% in mice. [1] |
| Synonyms | AUNP-12 acetate (1353563-85-5 Free base) |
| Molecular Weight | 3321.61 |
| Formula | C144H230N40O50 |
| Smiles | O=C([C@@](NC([C@](NC([C@@](NC([C@@](NC([C@@](NC([C@@](NN)(CCC(O)=O)[H])=O)(CCCCN)[H])=O)([C@@](CC)(C)[H])[H])=O)(CCC(N)=O)[H])=O)(C)[H])=O)(CCCCN)[H])N1[C@@](CCC1)(C(N[C@@](C(C([C@@](NC([C@@](NC([C@@](NC([C@@](NC([C@@](NC([C@@](NC(C(CCCCNN[C@@](CC2=CC=CC=C2)(C(N([H])[C@](C(N[C@@](C(CC(O)=O)([H])[H])(C(N[C@](C(N[C@@]([C@@](O)(C)[H])(C(N[C@@](CC(N)=O)(C(N[C@@](CO)(C([H])=O)[H])=O)[H])=O)[H])=O)(CO)[H])=O)[H])=O)(CO)[H])=O)[H])NC([C@@](N([H])C([C@@](NC([C@@](NC([C@@](NC([C@@](NC([C@@](NC([C@@](N)(CO)[H])=O)(CC(N)=O)[H])=O)([C@@](O)(C)[H])[H])=O)(CO)[H])=O)(CCC(O)=O)[H])=O)(CO)[H])=O)(CC3=CC=CC=C3)[H])=O)=O)(CC4=CC=CC=C4)[H])=O)(CCCNC(N)=N)[H])=O)(C(C)(C)[H])[H])=O)([C@@](O)(C)[H])[H])=O)(CCC(N)=O)[H])=O)(CC(C)C)[H])=O)=O)(C)[H])=O)[H].CC(O)=O |
| Sequence | Ser-Asn-Thr-Ser-Glu-Ser-Phe-Lys(1)-Phe-Arg-Val-Thr-Gln-Leu-Ala-Pro-Lys-Ala-Gln-Ile-Lys-Glu-NH2.H-Ser-Asn-Thr-Ser-Glu-Ser-Phe-(1) |
| Sequence Short | SNTSESFKF(H-SNTSESF)RVTQLAPKAQIKE |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (30.11 mM), Sonication is recommended. H2O: 25 mg/mL (7.53 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.